Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib in Advanced NSCLC with Uncommon EGFR Mutations
NCT05548348Phase 2Unknown
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Chongqing University Cancer Hospital. Status: unknown.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05548348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548348.